[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Comparative immunity update", "description": "High infection rates in UK, going down in US\n\nhttps://www.telegraph.co.uk/news/2021/10/19/people-must-cautious-day-to-day-interactions-covid-cases-climb/\n\nLower functional immunity in our population than most other \nWestern European countries\n\nEarly vaccine roll out\n\nAstraZeneca protects slightly less well than Pfizer against infection and transmission, particularly delta variant\n\nSlightly lower overall vaccination coverage, particularly vaccinating teenagers\n\nFewer social restrictions\n\nHigh rates of testing\n\nUK, ONS\n\n https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights\n\nTwo vaccine doses give similar protection as previous infection \n\nTwo doses of either Pfizer-BioNTech or Oxford-AstraZeneca\n\nProvided a similar level of protection as having had a previous natural infection of coronavirus\n\nDuring delta variant times\n\nVaccination reduced the risk of testing positive, \n\nboth when the alpha variant was dominant in the UK (1 December 2020 to 16 May 2021) \n\nand when the delta variant was dominant (17 May to 14 August 2021)\n\nTwo doses of Pfizer-BioNTech\n\nReduced the risk of testing positive by 73% in the delta period\n\nTwo doses of Oxford-AstraZeneca\n\nReduced the risk of testing positive by 62% in the delta period\n\nTwo vaccination doses, more effective than one at preventing symptomatic infection in both periods. \n\nThree weeks after vaccination\n\nTwo doses always more protective than one\n\n(75% v 58%)\n\nInconsistent with covid symptom study\n\nhttps://covid.joinzoe.com/post/do-i-need-a-covid-vaccine-if-ive-had-covid\n\nTwo doses of the Pfizer\n\n87% protection against infection\n\nTwo doses of the AstraZeneca\n\n71% protection against infection\n\nNatural infection alone\n\nOnly gave 65% protection against catching it again\n\nIsraeli data consistent with ONS but inconsistent with covid symptom study\n\nProtection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel\n https://www.medrxiv.org/content/10.1101/2021.04.20.21255670v1.full.pdf\n\nVaccination was highly effective \n\nEstimated efficacy for documented infection of 92\u00b78% \nHospitalization 94\u00b72% \nSevere illness 94\u00b74% \nDeath 93\u00b77% \n\nProtection from prior SARS-CoV-2 infection\n\nEstimated efficacy for documented infection of 94\u00b78% \nHospitalization 94\u00b71% \nSevere illness 96\u00b74%\n\nAll deaths registered in the week to 8 October \n\nCOVID-19 deaths fall in England, Northern Ireland and Scotland\nUp in Wales\n\nTotal UK deaths in the week, 12,490\n\n14.7% above the average in 2015 to 2019\n\n820 involved the coronavirus (COVID-19)\n\n154 fewer than the previous week\n\nDeaths involving COVID-19, 1 in 15 deaths (6.6%).\n\nUK total deaths include non-residents.\n\n1 million people in UK countries had COVID-19 in the latest week\n\n1.63% in England (1 in 60 people)\nOne in 70 people the week before\n\n2.18% in Wales (1 in 45 people)\nOne in 55 people the week before \n\n0.82% in Northern Ireland (1 in 120 people)\nOne in 130 people the week before\n \n1.26% in Scotland (1 in 80 people)\nOne in 60 people the week before\n\nGreg and Peter\nHello John, Just to let you know that one of my posts referring to your video on aspiration has been pulled from LinkedIn.   This is the first time that one of my posts has been pulled and I have put out some pretty controversial posts on other subjects.\n\nFeedback from vaccine manufacturers", "link": "https://www.youtube.com/watch?v=E89taTH86_s", "date_published": "2021-10-19 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "NIH and ivermectin", "description": "HIH, Table 2e. Characteristics of Antiviral Agents That Are Approved or Under Evaluation for the Treatment of COVID-19\n\nhttps://www.covid19treatmentguidelines.nih.gov/tables/table-2e/\n\nhttps://www.cms.gov/medicare/covid-19/new-covid-19-treatments-add-payment-nctap\n\nFDA live\n\nhttps://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19\n\nNIH live\n\nhttps://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ivermectin/\n\nAdults: Dosing Regimens\n\nThe dose most commonly used in clinical trials is IVM 0.2\u20130.6 mg/kg PO given as a single dose or as a once-daily dose for up to 5 days.\n\nAdverse events\n\nGenerally well tolerated\n\nDizziness\n\nPruritis\n\nGI effects (e.g., nausea, diarrhea)\n\nNeurological AEs have been reported when IVM has been used to treat parasitic diseases, \n\nbut it is not clear whether these AEs were caused by IVM or the underlying conditions.\n\nComments and links to clinical trials\n\nGenerally given on an empty stomach with water; however, administering IVM with food increases its bioavailability.\n\nA list of clinical trials is available here: Ivermectin\n\nRussia\n\nDeaths, \n\nhttps://coronavirus.jhu.edu/region/russia\n\nhttps://www.washingtonpost.com/world/europe/russia-covid-count-fake-statistics/2021/10/16/b9d47058-277f-11ec-8739-5cb6aba30a30_story.html\n\nIndependent demographer Alexey Raksha\n\nUsing data from Rosstat, Russia\u2019s statistical agency\n\nhttps://eng.rosstat.gov.ru/folder/11335\n\nExcess mortality, around 750,000\n\nhttps://www.themoscowtimes.com/2021/10/08/russias-coronavirus-excess-death-toll-hits-660k-a75254\n\nExcess mortality, around 660,000\n\nTracking cases around the world\n\nOfficials manipulated statistics and underplayed the crisis\n\nChina, Turkey\n\nhttps://www.washingtonpost.com/world/asia_pacific/world-health-organization-china-not-sharing-data-on-health-care-worker-coronavirus-infections/2020/02/26/28064fda-54e4-11ea-80ce-37a8d4266c09_story.html\n\nAlexei Kouprianov, independent analyst and biologist\n\nThe data for [Russia] is absolutely unreliable\n\nRecently ex St. Petersburg campus of the Higher School of Economics (September 2020)\n\nHandling of the pandemic, largely left to the regions\n\nRegional officials conceal problems, fear of losing their posts\n\nTherefore critics, even analytical experts, are sidelined\n\nIceland restricts Moderna\n\nhttps://www.landlaeknir.is/um-embaettid/frettir/frett/item47722/Aframhaldandi-notkun-COVID-19-boluefnis-Moderna-a-Islandi\n\nhttps://www.icelandreview.com/society/covid-19-in-iceland-moderna-vaccine-used-for-60/\n\nhttps://www.icelandreview.com/news/moderna-use-on-pause-in-iceland/\n\nChief Epidemiologist, \u00de\u00f3r\u00f3lfur Gu\u00f0nason\n\nModerna, only be used for booster shots in 60+\n\nUnpublished data from the Nordic countries indicate that the risk of cardiac inflammation after vaccination against COVID-19 is much higher among 18 to 39-year-olds if the Moderna vaccine is used than after vaccination with the Pfizer vaccine\n\nCardiac inflammation after vaccination is much less common among older demographics\n\nIn 12 to 17-year-olds, lack of European data\n\nUnder 60 who have received a single shot of Modern, to complete their vaccination with Pfizer\n\nMen 18-39 are not recommended to accept the Moderna COVID-19 vaccine\nIceland data, vast majority of vaccination side effects emerge shortly after vaccination", "link": "https://www.youtube.com/watch?v=2F-Ml9gHnqA", "date_published": "2021-10-18 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]